Policy: How to regulate faecal transplants
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, FMT is also approved for treating CDI, and it is considered safe and effective.14”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [14]
Citations
Cites
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
The human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
(1958) · PubMed · Cited by 978
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Petrof, E. O., Gloor, G. B., Vanner, S. J., Weese, S. J., Carter, D., Daigneault, M. C., Brown, E. M., Schroeter, K., & Allen-Vercoe, E. (2013) · Microbiome · doi:10.1186/2049-2618-1-3 · Cited by 731
Therapeutic Potential of Fecal Microbiota Transplantation
Smits, L. P., Bouter, K. E. C., de Vos, W. M., Borody, T. J., & Nieuwdorp, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.058 · Cited by 717
Lawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002995 · Cited by 540
The gut microbiome: the role of a virtual organ in the endocrinology of the host
Evans, J. M., Morris, L. S., & Marchesi, J. R. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0131 · Cited by 264
Fecal microbiota transplantation: facts and controversies
van Nood, E., Speelman, P., Nieuwdorp, M., & Keller, J. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000024 · Cited by 92
Research works printed but not linked: 1
- Eiseman, B., Silen, W., Bascom, G. S. & Kauvar, A. J. Surgery 44, 854–859 (1958).
Cited by
Gut microbiota in colorectal cancer: mechanisms of action and clinical applications
Wong, S. H., & Yu, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0209-8 · Cited by 1,331
Gut microbiota modulation of chemotherapy efficacy and toxicity
Alexander, J. L., Wilson, I. D., Teare, J., Marchesi, J. R., Nicholson, J. K., & Kinross, J. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.20 · Cited by 970
Bajaj, J. S., Kassam, Z., Fagan, A., Gavis, E. A., Liu, E., Cox, I. J., Kheradman, R., Heuman, D., Wang, J., Gurry, T., et al. (2017) · Hepatology · doi:10.1002/hep.29306 · Cited by 633
“Fecal microbiota transplants (FMTs) have been shown, in randomized controlled trials, to be effective in dysbiotic conditions such as recurrent Clostridium difficile and ulcerative colitis.((16-19)) Cross-sectional data demonstrating microbial dysbiosis in HE((20)) and a case report((21)) suggest that FMT may be promi…”
BackgroundSelf-citationFecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Understanding the mechanisms of faecal microbiota transplantation
Khoruts, A., & Sadowsky, M. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.98 · Cited by 561
Durable coexistence of donor and recipient strains after fecal microbiota transplantation
Li, S. S., Zhu, A., Benes, V., Costea, P. I., Hercog, R., Hildebrand, F., Huerta-Cepas, J., Nieuwdorp, M., Salojärvi, J., Voigt, A. Y., et al. (2016) · Science · doi:10.1126/science.aad8852 · Cited by 547
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Paramsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
Manipulating the gut microbiota to maintain health and treat disease
Scott, K. P., Antoine, J.-M., Midtvedt, T., & van Hemert, S. (2015) · Microbial Ecology in Health & Disease · doi:10.3402/mehd.v26.25877 · Cited by 281
Panek, M., Čipčić Paljetak, H., Barešić, A., Perić, M., Matijašić, M., Lojkić, I., Vranešić Bender, D., Krznarić, Ž., & Verbanac, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-23296-4 · Cited by 186
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.006 · Cited by 180
“Thus, regulation of FMT has been advocated (Smith et al., 2014), and FDA has recently driven efforts in that direction (Mole, 2013).”
BackgroundHow to: establish and run a stool bank
Terveer, E. M., van Beurden, Y. H., Goorhuis, A., Seegers, J. F. M. L., Bauer, M. P., van Nood, E., Dijkgraaf, M. G. W., Mulder, C. J. J., Vandenbroucke-Grauls, C. M. J. E., Verspaget, H. W., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.05.015 · Cited by 168
“Although FMT appears to be a typical transplantation product to most experts in the field [12], it does not fulfil the criteria for guidance by the EU tissue and cell transplantation act, because the cellular component of FMT appears not to be the active substance.”
BackgroundDonor Recruitment for Fecal Microbiota Transplantation
Paramsothy, S., Borody, T. J., Lin, E., Finlayson, S., Walsh, A. J., Samuel, D., van den Bogaerde, J., Leong, R. W. L., Connor, S., Ng, W., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000405 · Cited by 149
“T he last few years has seen exponential growth in the use of fecal microbiota transplantation (FMT).(1) This has primarily been in the treatment of recurrent Clostridium difficile infection (rCDI), for which FMT is now widely accepted as the most effective therapy available, being listed as a treatment strategy for C…”
MethodClostridium Difficile Infection
Lübbert, C., John, E., & von Müller, L. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0723 · Cited by 178
Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review
Woodworth, M. H., Carpentieri, C., Sitchenko, K. L., & Kraft, C. S. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1286006 · Cited by 144
The role of gut microbiota and metabolites in cancer chemotherapy
Li, S., Zhu, S., & Yu, J. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.027 · Cited by 114
Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review
Bafeta, A., Yavchitz, A., Riveros, C., Batista, R., & Ravaud, P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2810 · Cited by 111
“Reporting of screening for all medications taken by donor 8 (9)”
BackgroundCostello, S. P., Tucker, E. C., La Brooy, J., Schoeman, M. N., & Andrews, J. M. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ994 · Cited by 105
Ethical Issues in Fecal Microbiota Transplantation in Practice
Ma, Y., Liu, J., Rhodes, C., Nie, Y., & Zhang, F. (2017) · The American Journal of Bioethics · doi:10.1080/15265161.2017.1299240 · Cited by 91
“Second, the FDA’s strict regulation of fecal microbiota as a drug actually dissuades doctors from using the product and limits access to care (Smith, Kelly, and Alm 2014).”
BackgroundInfluentialStandardized Preparation for Fecal Microbiota Transplantation in Pigs
Hu, J. P., Chen, L., Tang, Y., Xie, C., Xu, B., Shi, M. Y., Zheng, W., Zhou, S., Wang, X., Liu, L., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01328 · Cited by 100
“More and more clinical applications of FMT have provided convincing proofs that modification of the intestinal microbiota is an effective therapy for intestinal dysbiosis-related diseases (Sekirov and Finlay, 2009; Smits et al., 2013).”
Clostridium difficile Drug Pipeline: Challenges in Discovery and Development of New Agents
Jarrad, A. M., Karoli, T., Blaskovich, M. A. T., Lyras, D., & Cooper, M. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5016846 · Cited by 97
Gut microbiota and obesity: implications for fecal microbiota transplantation therapy
Kang, Y., & Cai, Y. (2017) · HORMONES · doi:10.14310/horm.2002.1742 · Cited by 90
Emerging Frontiers in Microbiome Engineering
Inda, M. E., Broset, E., Lu, T. K., & de la Fuente‐Núñez, C. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.08.007 · Cited by 78
“For example, fecal transplant to treat Clostridium difficile diarrhea is clinically successful in humans [7]; nevertheless, it is difficult to standardize and such therapies can also perturb the microbiome quite broadly [8], as the FDA has also warned [9].”
BackgroundMao, Z., Gao, Z., Liu, D., Liu, Z., & Wu, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1124704 · Cited by 73
Studying microbial functionality within the gut ecosystem by systems biology
Hornung, B., Martins dos Santos, V. A. P., Smidt, H., & Schaap, P. J. (2018) · Genes & Nutrition · doi:10.1186/s12263-018-0594-6 · Cited by 53
Khanna, S., Sims, M. D., Louie, T., Fischer, M., LaPlante, K. L., Allegretti, J. R., Hasson, B. R., Fonte, A. T., McChalicher, C. W. J., Ege, D. S., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11091234 · Cited by 61
Allegretti, J. R., Kassam, Z., Osman, M., Budree, S., Fischer, M., & Kelly, C. R. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.05.036 · Cited by 63
Self-citationDevelopment of Fecal Microbiota Transplantation Suitable for Mainstream Medicine
Khoruts, A., Sadowsky, M. J., & Hamilton, M. J. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.014 · Cited by 58
Hevia, A., Delgado, S., Margolles, A., & Sánchez, B. (2015) · Scientific Reports · doi:10.1038/srep16807 · Cited by 57
Improving regulation of microbiota transplants
Hoffmann, D., Palumbo, F., Ravel, J., Roghmann, M.-C., Rowthorn, V., & von Rosenvinge, E. (2017) · Science · doi:10.1126/science.aaq0034 · Cited by 51
Fecal transplant policy and legislation
Vyas, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i1.6 · Cited by 51
Impact of the microbiome on cancer progression and response to anti-cancer therapies
Rosean, C. B., Feng, T.-Y., Azar, F. N., & Rutkowski, M. R. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.005 · Cited by 55
“The FDA is now evaluating methods of regulation for these transplants, including designating feces as a medication that requires approval as an Investigational New Drug (IND) (Smith et al., 2014).”
MethodHuman microbiome restoration and safety
Daliri, E. B.-M., Tango, C. N., Lee, B. H., & Oh, D.-H. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2018.05.002 · Cited by 48
Merlo, G., Graves, N., Brain, D., & Connelly, L. B. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13402 · Cited by 50
Faecal microbiota transplantation: establishment of a clinical application framework
Jørgensen, S. M. D., Hansen, M. M., Erikstrup, C., Dahlerup, J. F., & Hvas, C. L. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000958 · Cited by 47
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
“There is, however, controversy on how and if fecal transplant should be regulated, and the FDApresently is considering feces as a drug that requires an investigational new drug approval (58).”
Probiotic strains and mechanistic insights for the treatment of type 2 diabetes
Hampe, C. S., & Roth, C. L. (2017) · Endocrine · doi:10.1007/s12020-017-1433-z · Cited by 49
Optimal screening and donor management in a public stool bank
Kazerouni, A., Burgess, J., Burns, L. J., & Wein, L. M. (2015) · Microbiome · doi:10.1186/s40168-015-0140-3 · Cited by 43
From hype to hope: Considerations in conducting robust microbiome science
McGuinness, A. J., Stinson, L. F., Snelson, M., Loughman, A., Stringer, A. M., Hannan, A. J., Cowan, C. S. M., Jama, H. A., Caparros-Martin, J. A., West, M. L., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.09.022 · Cited by 46
“Of major concern are reports of individuals attempting “ do-it-yourself ” home FMTs based on online videos, books, and anecdotal experiences (Smith et al., 2014), the dangers of which have been highlighted by recent deaths associated with the transfer of antimicrobial resistance genes (Green et…”
OpenBiome remains open to serve the medical community
Smith, M. B., Kassam, Z., Edelstein, C. A., Burgess, J., & Alm, E. J. (2014) · Nature Biotechnology · doi:10.1038/nbt.3006 · Cited by 44
Self-citationStructural forecasting of species persistence under changing environments
Saavedra, S., Medeiros, L. P., & AlAdwani, M. (2020) · Ecology Letters · doi:10.1111/ele.13582 · Cited by 45
Yue, B., Yu, Z., Lv, C., Geng, X., Wang, Z., & Dou, W. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i30.4378 · Cited by 38
Kazerouni, A., & Wein, L. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0163956 · Cited by 37
Fecal microbiota transplantation, a tool to transfer healthy longevity
Novelle, M. G., Naranjo-Martínez, B., Lopez-Canovas, J. L., & Díaz‐Ruiz, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102585 · Cited by 37
“FMT, now recognized as a unique form of organ transplant, is currently undergoing extensive exploration in various fields of therapy to address both chronic intestinal conditions and extra-intestinal health issues (Jain et al., 2023; Smith et al., 2014).”
Gastroenterologist perceptions of faecal microbiota transplantation
Paramsothy, S., Walsh, A. J., Borody, T., Samuel, D., van den Bogaerde, J., Leong, R. W., Connor, S., Ng, W., Mitchell, H. M., Kaakoush, N. O., et al. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i38.10907 · Cited by 40
Faecal microbiota transplantation: a regulatory hurdle?
Verbeke, F., Janssens, Y., Wynendaele, E., & Spiegeleer, B. D. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0687-5 · Cited by 40
“Although faecal microbiota transplantation retains the drug status, currently this policy of tolerance remains [70].”
BackgroundThe Oncobiome in Gastroenteric and Genitourinary Cancers
D’Antonio, D. L., Marchetti, S., Pignatelli, P., Piattelli, A., & Curia, M. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179664 · Cited by 36
Advances in the Microbiome: Applications to Clostridium difficile Infection
Culligan, E. P., & Sleator, R. D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090083 · Cited by 39
“Other authors have argued that FMT could be regulated as tissue, rather than a drug or given its own classification altogether [51].”
BackgroundKassam, Z., Lee, C., & Hunt, R. H. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.08.007 · Cited by 34
How to Manipulate the Microbiota: Fecal Microbiota Transplantation
Fuentes, S., & de Vos, W. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-31248-4_10 · Cited by 31
Han, S. S., Shannahan, S. E., & Pellish, R. S. (2016) · Journal of Intensive Care Medicine · doi:10.1177/0885066615594344 · Cited by 34
“The stool bank screens donors for infectious agents as well as for chronic conditions, and samples are frozen for long-term storage.(96) As this increases access to stool for FMT, there are interesting questions regarding possible differences in frozen stool samples from anonymous donors versus fresh donated stool fro…”
BackgroundFaecal microbiota transplantation: from practice to legislation before considering industrialization
Lagier, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12795 · Cited by 34
“Faecal microbiota is a variable and complex ecosystem composed of a mixture of microorganisms, metabolites, and human cells [17,19,22].”
BackgroundInfluentialChoi, Y. J., Kim, J. E., Lee, S. J., Gong, J. E., Son, H. J., Hong, J. T., & Hwang, D. Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.650789 · Cited by 31
The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation
Khoruts, A., Hoffmann, D. E., & Palumbo, F. B. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519897726 · Cited by 28
Rejuvenating the human gut microbiome
Ke, S., Weiss, S. T., & Liu, Y. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.005 · Cited by 27
Investigational new treatments for Clostridium difficile infection
Ivarsson, M. E., Leroux, J., & Castagner, B. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.12.003 · Cited by 33
Self-tracking the microbiome: where do we go from here?
Gimbert, C., & Lapointe, F. (2015) · Microbiome · doi:10.1186/s40168-015-0138-x · Cited by 27
Scheeler, A. (2019) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110519897729 · Cited by 28
Hu, C., Liu, M., Sun, B., Tang, L., Zhou, X., & Chen, L. (2022) · Environment International · doi:10.1016/j.envint.2022.107418 · Cited by 26
Antibiotic and Modulation of Microbiota: A New Paradigm?
Rizzatti, G., Ianiro, G., & Gasbarrini, A. (2018) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001069 · Cited by 28
Establishing a donor stool bank for faecal microbiota transplantation: methods and feasibility
Rode, A. A., Bytzer, P. M., Pedersen, O. B., & Engberg, J. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03615-x · Cited by 25
Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus
Zhou, X., Chen, R., Cai, Y., & Chen, Q. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447784 · Cited by 25
“106 110 In addition, Alang and Kelly report an example of a patient who became obese after FMT, so we focus on the requirement that the donor does not have T2DM or other metabolism-related diseases and has normal fasting glucose and insulin levels.”
BackgroundMahmoudi, H., & Hossainpour, H. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_131_22 · Cited by 27
“Excellence; UK: United Kingdom; IABS: International Alliance for Biological Standardization.[13-19]”
BackgroundEdelstein, C. A., Kassam, Z., Daw, J. R., Smith, M. B., & Kelly, C. R. (2015) · Clinical Research and Regulatory Affairs · doi:10.3109/10601333.2015.1046602 · Cited by 24
“In the subsequent 50 years, but most recently over the last 5 years, there has been a rise in promising evidence for the utility of FMT, particularly for recurrent Clostridium difficile infection (CDI) (8).”
BackgroundInfluentialSelf-citationHu, C., Sun, B., Liu, M., Yu, J., Zhou, X., & Chen, L. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153758 · Cited by 23
Understanding the impact of third-party species on pairwise coexistence
Deng, J., Taylor, W., & Saavedra, S. (2022) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1010630 · Cited by 20
Gut inflammation and microbiome in spondyloarthritis
Kabeerdoss, J., Sandhya, P., & Danda, D. (2015) · Rheumatology International · doi:10.1007/s00296-015-3414-y · Cited by 23
Lübbert, C., Salzberger, B., & Mössner, J. (2017) · Der Internist · doi:10.1007/s00108-017-0203-6 · Cited by 24
Clostridium Difficile Infection: Risk Factors, Diagnosis and Management
Surawicz, C. M. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-014-0038-3 · Cited by 21
Conventional and alternative treatment approaches for Clostridium difficile infection.
Aljarallah, K. M. (2017) · PubMed Central · Cited by 24
Faecal microbiota transplantation: A sui generis biological drug, not a tissue
Megerlin, F., Fouassier, É., Lopert, R., & Bourlioux, P. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.04.008 · Cited by 19
“Smith and colleagues argue that for medical use, human tool should be considered a tissue — not a drug [3].”
BackgroundInfluentialBiobanking for human microbiome research: promise, risks, and ethics
Ma, Y., Chen, H., Lei, R., & Ren, J. (2017) · Asian Bioethics Review · doi:10.1007/s41649-017-0033-9 · Cited by 18
Yu, F., Zhong, Y., Zhang, B., Zhou, Y., He, M., Yang, Y., Wang, Q., Yang, X., Ren, X., Qian, J., et al. (2024) · Small · doi:10.1002/smll.202308071 · Cited by 16
Novel opportunities for the exploitation of host–microbiome interactions in the intestine
Claes, I. J. J., Garcia, C. V., & Lebeer, S. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.10.008 · Cited by 17
“Apparently, regulatory issues are currently imposing a burden on the further development of FMT and synthetic alternatives, but scientists and regulatory authorities such as the US Food and Drug Administration (FDA) are gradually joining forces to work out solutions and applicable directives [16].”
BackgroundSinnathamby, E. S., Mason, J. W., Flanagan, C. J., Pearl, N. Z., Burroughs, C. R., Witt, A. J. D., Wenger, D. M., Klapper, V. G., Ahmadzadeh, S., Varrassi, G., et al. (2023) · Cureus · doi:10.7759/cureus.51167 · Cited by 16
Practical implementation of faecal transplantation
Kapel, N., Thomas, M., Corcos, O., Mayeur, C., Barbot, L., Bouhnik, Y., & Joly, F. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12796 · Cited by 16
“[11] argue that, for medical uses, the human stool should be considered a tissue, and not a drug.”
BackgroundMedical students’ perception on fecal microbiota transplantation
Madar, P. C., Petre, O., Băban, A., & Dumitrascu, D. L. (2019) · BMC Medical Education · doi:10.1186/s12909-019-1804-7 · Cited by 15
Gut Microbial Dysbiosis in the Pathogenesis of Leukemia: An Immune-based Perspective.
Goswami, M., & Bose, P. D. (2024) · Experimental Hematology · doi:10.1016/j.exphem.2024.104211 · Cited by 12
Walia, R., Kunde, S. S., & Mahajan, L. A. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000127 · Cited by 16
“More recently, stool banks have emerged nationally and within hospitals to provide rapidly available, cost-effective supplies of stool from screened donors [21,23].”
BackgroundVerbeken, G., Huys, I., Vos, D. D., Coninck, A. D., Roseeuw, D. I., Kets, E., Vanderkelen, A., Draye, J. P., Rose, T., Jennes, S., et al. (2015) · FEMS Microbiology Letters · doi:10.1093/femsle/fnv241 · Cited by 14
Generalizing game-changing species across microbial communities
Deng, J., Angulo, M. T., & Saavedra, S. (2021) · ISME Communications · doi:10.1038/s43705-021-00022-2 · Cited by 16
Schenck, L. P., Beck, P. L., & MacDonald, J. A. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i4.169 · Cited by 22
Liu, M., Sun, B., Zhou, X., & Chen, L. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113721 · Cited by 13
Physicians' Knowledge and Attitude Towards Fecal Microbiota Transplant in Iran.
Moossavi, S., Salimzadeh, H., Katoonizadeh, A., Mojarrad, A., Merat, D., Ansari, R., Vahedi, H., Merat, S., & Malekzadeh, R. (2015) · PubMed Central · Cited by 13
Proportionality in Public Health Regulation: The Case of Dietary Supplements
Resnik, D. B. (2017) · Food Ethics · doi:10.1007/s41055-017-0023-3 · Cited by 14
“In 2014, the FDA reversed its position on fecal matter after hearing testimony from physicians and representatives from the Centers for Diseases Control and Prevention and several medical organizations (Smith et al. 2014).”
BackgroundInfluentialBono‐Lunn, D., Villeneuve, C., Abdulhay, N. J., Harker, M. J., & Parker, W. (2016) · Clinical Research and Regulatory Affairs · doi:10.1080/10601333.2016.1210159 · Cited by 12
“The painfully slow pace at which fecal microbiota transplants have been implemented by modern medical practitioners has been attributed in part to regulatory hurdles (58).”
BackgroundWu, W., Shen, N., Luo, L., Deng, Z., Chen, J., Tao, Y., Mo, X., & Cao, Q. (2020) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2020.11.003 · Cited by 13
Laperrousaz, B., Levast, B., Fontaine, M., Nancey, S., Déchelotte, P., Dore, J. M., & Lehert, P. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03487-2 · Cited by 12
“A greater number of donors contributing to a FMT preparation increases the chance of altering the recipient’s gut microbiome to the extent that they become prone to developing chronic conditions (e.g., autoimmune disorders) [47].”
BackgroundGeorgescu, M. (2018) · FARMACIA · doi:10.31925/farmacia.2018.4.1 · Cited by 11
“Intestinal microbiota transplantation (IMT) is also cited in current international guidelines as adjunctive treatment option for advanced CDI [61], but important”
BackgroundGweon, T., Lee, Y. J., Yim, S. K., Kim, S. Y., Choi, C. H., & Cho, Y. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.206 · Cited by 10
“Physicians have raised concerns that the policy of the FDA could restrict FMT and argue that FMT should be managed in the same way as a blood transfusion rather than as a drug or as a solid organ transplantation [23].”
BackgroundDietary fungi in cancer immunotherapy: From the perspective of gut microbiota
Wei, Y., Song, D., Wang, R., Li, T., Wang, H., & Li, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1038710 · Cited by 9
“Fecal microbiota transplantation (FMT) and single bacteria transplantation (probiotic administration) have achieved promising results in improving the wellness of patients, however, it may be detrimental for patients exposed to the allogenic strains for FMT and make people vulnerable to chronic diseases such as autoim…”
BackgroundKoh, A. Y. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.259499 · Cited by 9
Disgust, Need for Affect, and Responses to Microbiome Research
Sun, Y., Yeo, S. K., McKasy, M., & Shugart, E. C. (2019) · Mass Communication & Society · doi:10.1080/15205436.2019.1565786 · Cited by 9
Le transfert de microbiote intestinal à finalité thérapeutique : quel droit applicable en France ?
Megerlin, F., & Fouassier, É. (2014) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2014.04.003 · Cited by 9
Lou, P., Shen, Y., Zhuge, A., Lv, L., Zhu, X., Yin, Y., Yang, L., Wang, K., Li, B., & Li, L. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01847-21 · Cited by 10
“enteral tubing, its standardization, safety, and effectiveness require further study (8, 9).”
BackgroundEndoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease
Kerman, D. H. (2016) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2016.06.006 · Cited by 10
Tungland, B. C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814649-1.00009-0 · Cited by 10
Sun, B., Liu, M., Tang, L., Zhou, X., Hu, C., & Chen, L. (2022) · Journal of Environmental Sciences · doi:10.1016/j.jes.2022.06.019 · Cited by 7
Les enjeux médicaux et sociétaux du microbiote
Dodet, B. (2016) · médecine/sciences · doi:10.1051/medsci/20163211017 · Cited by 7
Metadata
- Authors
- Smith, M. B., Kelly, C., & Alm, E. J.
- Affiliations
- Massachusetts Institute of Technology (US)
- Brown University (US)
- Corresponding author
- Alm, Eric J.
- Venue
- Nature
- Published
- 2014-02-19
- Volume
- 506
- Issue
- 7488
- Pages
- 290-291
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2069630918
- Cited by
- 140
- References
- 10
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 7 · 2020: 10 · 2019: 12 · 2018: 10 · 2017: 22 · 2016: 13 · 2015: 20 · 2014: 18
- FWCI
- 15.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Keywords
- fecal microbiota transplantation, regulatory policy, human microbiome
- MeSH terms
- Animals, Clostridium Infections, Feces, Humans, United States, United States Food and Drug Administration, Clostridioides difficile, Tissue Transplantation, Controlled Clinical Trials as Topic, Mice, Compassionate Use Trials, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.